GeneReach Biotechnology (Taiwan) Today
| 4171 Stock | TWD 26.75 0.50 1.83% |
Performance0 of 100
| Odds Of DistressLess than 10
|
GeneReach Biotechnology is selling for under 26.75 as of the 14th of December 2024; that is 1.83% down since the beginning of the trading day. The stock's lowest day price was 26.75. GeneReach Biotechnology has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of June 2024 and ending today, the 14th of December 2024. Click here to learn more.
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan. GENEREACH BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.. The company has 45.97 M outstanding shares. More on GeneReach Biotechnology
Moving together with GeneReach Stock
| 0.77 | 4743 | Oneness Biotech | PairCorr |
| 0.86 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.9 | 4174 | OBI Pharma | PairCorr |
Moving against GeneReach Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
GeneReach Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. GeneReach Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding GeneReach Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | Biotech (View all Themes) |
| Business Concentration | Biotech, Biotechnology, Healthcare (View all Sectors) |
GeneReach Biotechnology (4171) is traded on Taiwan OTC Exchange in Taiwan and employs 16 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.73 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate GeneReach Biotechnology's market, we take the total number of its shares issued and multiply it by GeneReach Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. GeneReach Biotechnology operates under Healthcare sector and is part of Biotechnology industry. The entity has 45.97 M outstanding shares.
GeneReach Biotechnology has accumulated about 811.4 M in cash with 348.99 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.65.
Check GeneReach Biotechnology Probability Of Bankruptcy
Ownership AllocationGeneReach Biotechnology has a total of 45.97 Million outstanding shares. GeneReach Biotechnology secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check GeneReach Ownership Details
GeneReach Biotechnology Risk Profiles
Although GeneReach Biotechnology's alpha and beta are two of the key measurements used to evaluate GeneReach Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.8424 | |||
| Standard Deviation | 1.14 | |||
| Variance | 1.3 | |||
| Risk Adjusted Performance | (0.16) |
GeneReach Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in GeneReach Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
GeneReach Biotechnology Corporate Management
Elected by the shareholders, the GeneReach Biotechnology's board of directors comprises two types of representatives: GeneReach Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneReach. The board's role is to monitor GeneReach Biotechnology's management team and ensure that shareholders' interests are well served. GeneReach Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneReach Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alison Lee | Chief Officer | Profile | |
| Grace Chang | Chief Officer | Profile | |
| David Tsai | Chief Officer | Profile | |
| Simon Chung | Chief Officer | Profile | |
| Yuwen Huang | Deputy General Manager-Compliance & Production | Profile |
Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.